Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avycaz Pharmacokinetics in Cystic Fibrosis
NCT02504827Phase 4Completed
- Sponsor
- University of Southern California
- Start
- Sep 2015
- Primary completion
- Oct 2016
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ceftazidime + avibactam in cystic fibrosis (CF), sponsored by University of Southern California. Primary endpoints: Peak Plasma Concentration at 8 hours and Peak Sputum Concentration at 8 hours. Started Sep 2015; status: completed.
02
Drugs
ceftazidime + avibactam
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02504827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02504827.